Cellular interactions in prostate cancer genesis and dissemination. Looking beyond the obvious

Romanian Journal of Morphology and Embryology

Volumn 51, Issue 3, 2010, Pages 427-435

  Tomuleasa, C ^a   Kacso G ^a   Soriţǎu, Olga ^a   Susman S ^b   Irimie, A ^a   Virág, Piroska ^a  

^a 'Ion Chiricu ' Comprehensive Cancer Center   (Romania)

^b IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Cell plasticity; Prostate cancer stem cells; Stem cell niche

Indexed keywords

CANCER STEM CELL; CELL COMMUNICATION; DRUG RESISTANCE; HUMAN; MALE; METASTASIS; PATHOLOGY; PRECANCER; PRENATAL DEVELOPMENT; PROSTATE TUMOR; REVIEW; STEM CELL NICHE; TUMOR EMBOLISM;

CELL COMMUNICATION; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; NEOPLASTIC STEM CELLS; PRECANCEROUS CONDITIONS; PROSTATIC NEOPLASMS; STEM CELL NICHE;

EID: 77957010948     PISSN: 12200522     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. SCHRÖDER FH, HUGOSSON J, ROOBOL MJ, TAMMELA TL, CIATTO S, NELEN V, KWIATKOWSKI M, LUJAN M, LILJA H, ZAPPA M, DENIS LJ, RECKER F, BERENGUER A, MÄÄTTÄNEN L, BANGMA CH, AUS G, VILLERS A, REBILLARD X, VAN DER KWAST T, BLIJENBERG BG, MOSS SM, DE KONING HJ, AUVINEN A; ERSPC INVESTIGATORS, Screening and prostate-cancer mortality in a randomized European study, N Engl J Med, 2009, 360(13):1320-1328.
2. ANDRIOLE GL, CRAWFORD ED, GRUBB RL 3RD, BUYS SS, CHIA D, CHURCH TR, FOUAD MN, GELMANN EP, KVALE PA, REDING DJ, WEISSFELD JL, YOKOCHI LA, O'BRIEN B, CLAPP JD, RATHMELL JM, RILEY TL, HAYES RB, KRAMER BS, IZMIRLIAN G, MILLER AB, PINSKY PF, PROROK PC, GOHAGAN JK, BERG CD; PLCO PROJECT TEAM, Mortality results from a randomized prostate-cancer screening trial, N Engl J Med, 2009, 360(13):1310-1319.
3. HESSELS D, KLEIN GUNNEWIEK JM, VAN OORT I, KARTHAUS HF, VAN LEENDERS GJ, VAN BALKEN B, KIEMENEY LA, WITJES JA, SCHALKEN JA, DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer, Eur Urol, 2003, 44(1):8-15.
4. ORNSTEIN DK, RAYFORD W, FUSARO VA, CONRADS TP, ROSS SJ, HITT BA, WIGGINS WW, VEENSTRA TD, LIOTTA LA, PETRICOIN EF 3RD, Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml, J Urol, 2004, 172(4 Pt 1):1302-1305.
5. THOMPSON I, THRASHER JB, AUS G, BURNETT AL, CANBYHAGINO ED, COOKSON MS, D'AMICO AV, DMOCHOWSKI RR, ETON DT, FORMAN JD, GOLDENBERG SL, HERNANDEZ J, HIGANO CS, KRAUS SR, MOUL JW, TANGEN CM; AUA PROSTATE CANCER CLINICAL GUIDELINE UPDATE PANEL, Guidelines for the management of clinically localized prostate cancer: 2007 update, J Urol, 2007, 177(6):2106-2131.
6. ROCCHI P, SO A, KOJIMA S, SIGNAEVSKY M, BERALDI E, FAZLI L, HURTADO-COLL A, YAMANAKA K, GLEAVE M, Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractary prostate cancer, Cancer Res, 2004, 64(18):6595-6602.
7. TANNOCK IF, DE WIT R, BERRY WR, HORTI J, PLUZANSKA A, CHI KN, OUDARD S, THÉODORE C, JAMES ND, TURESSON I, ROSENTHAL MA, EISENBERGER MA; TAX 327 INVESTIGATORS, Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer, N Engl J Med, 2004, 351(15):1502-1512.
8. SOUHAMI L, BAE K, PILEPICH M, SANDLER H, Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy: a secondary analysis of RTOG 85-31, J Clin Oncol, 2009, 27(13):2137-2143.
9. DEVENS BH, WEEKS RS, BURNS MR, CARLSON CL, BRAWER MK, Polyamine depletion therapy in prostate cancer, Prostate Cancer Prostatic Dis, 2000, 3(4):275-279.
10. SHEN MM, WANG X, ECONOMIDES KD, WALKER D, ABATESHEN C, Progenitor cells for the prostate epithelium: roles in development, regeneration, and cancer, Cold Spring Harb Symp Quant Biol, 2008, 73:529-538.
11. TIMMS BG, MOHS TJ, DIDIO LJ, Ductal budding and branching patterns in the developing prostate, J Urol, 1994, 151(5):1427-1432.
12. COLLINS AT, MAITLAND NJ, Prostate cancer stem cells, Eur J Cancer, 2006, 42(9):1213-1218.
13. NIKITIN AY, MATOSO A, ROY-BURMAN P, Prostate stem cells and cancer, Histol Histopathol, 2007, 22(9):1043-1049.
14. WANG Y, HAYWARD S, CAO M, THAYER K, CUNHA G, Cell differentiation lineage in the prostate, Differentiation, 2001, 68(4-5):270-279.
15. BONKHOFF H, WERNERT N, DHOM G, REMBERGER K, Relation of endocrine-paracrine cells to cell proliferation in normal, hyperplastic, and neoplastic human prostate, Prostate, 1991, 19(2):91-98.
16. SKARIN AT (ed), Atlas of diagnostic oncology, 2nd edition, Mosby-Wolfe, London, 1996, 465-552.
17. DE MARZO AM, MEEKER AK, EPSTEIN JI, COFFEY DS, Prostate stem cell compartments: expression of the cell cycle inhibitor p27Kip1 in normal, hyperplastic, and neoplastic cells, Am J Pathol, 1998, 153(3):911-919.
18. TSUJIMURA A, KOIKAWA Y, SALM S, TAKAO T, COETZEE S, MOSCATELLI D, SHAPIRO E, LEPOR H, SUN TT, WILSON EL, Proximal location of mouse prostate epithelial stem cells: a model of prostatic homeostasis, J Cell Biol, 2002, 157(7):1257-1265.
19. TOMULEASA C, SORITAU O, RUS-CIUCA D, POP T, TODEA D,MOSTEANU O, PINTEA B, FORIS V, SUSMAN S, KACSO G, IRIMIE A Isolation and characterization of hepatic cancer cells with stem-like properties from hepatocellular carcinoma, J Gastrointestin Liv Dis, 2010, 19(1):61-67.
20. TOMULEASA C, SORIŢǍU O, RUS-CIUCǍ D, FORIS V, IOANI H, ŞUŞMAN S, PETRESCU M, MIHU C, CERNEA D, FLORIAN IST, KACSÓ G, IRIMIE AL, Functional and molecular characterization of glioblastoma multiforme-derived brain cancer stem cells, J BUON, 2010, in press.
21. COLLINS AT, BERRY PA, HYDE C, STOWER MJ, MAITLAND NJ, Prospective identification of tumorigenic prostate cancer stem cells, Cancer Res, 2005, 65(23):10946-10951.
22. GU G, YUAN J, WILLS M, KASPER S, Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo, Cancer Res, 2007, 67(10):4807-4815.
23. HONORIO S, LI H, TANG DG, Prostate cancer stem/progenitor cells. In: BAGLEY RG, TEICHER BA (eds), Stem cells and cancer, Springer Science, New York, 2009, 217-231.
24. SKVORTSOVA I, SKVORTSOV S, STASYK T, RAJU U, POPPER BA, SCHIESTL B, VON GUGGENBERG E, NEHER A, BONN GK, HUBER LA, LUKAS P, Intracellular signaling pathways regulating radioresistance of human prostate carcinoma cells, Proteomics, 2008, 8(21):4521-4533.
25. STAVROVSKAYA AA, STROMSKAYA TP, Transport proteins of the ABC family and multidrug resistance of tumor cells, Biochemistry (Mosc), 2008, 73(5):592-604.
26. ATTARD G, SWENNENHUIS JF, OLMOS D, REID AH, VICKERS E, A'HERN R, LEVINK R, COUMANS F, MOREIRA J, RIISNAES R, OOMMEN NB, HAWCHE G, JAMESON C, THOMPSON E, SIPKEMA R, CARDEN CP, PARKER C, DEARNALEY D, KAYE SB, COOPER CS, MOLINA A, COX ME, TERSTAPPEN LW, DE BONO JS, Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer, Cancer Res, 2009, 69(7):2912-2918.
27. LU X, LEGERSKI RJ, The Prp19/Pso4 core complex undergoes ubiquitylation and structural alterations in response to DNA damage, Biochem Biophys Res Commun, 2007, 354(4):968-974.
28. ZHANG D, TAI LK, WONG LL, CHIU LL, SETHI SK, KOAY ES, Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer, Mol Cell Proteomics, 2005, 4(11):1686-1696.
29. HILL RP, MARIE-EGYPTIENNE DT, HEDLEY DW, Cancer stem cells, hypoxia and metastasis, Semin Radiat Oncol, 2009, 19(2):106-111.
30. DAS B, TSUCHIDA R, MALKIN D, KOREN G, BARUCHEL S, YEGER H, Hypoxia enhances tumor stemness by increasing the invasive and tumorigenic side population fraction, Stem Cells, 2008, 26(7):1818-1830.
31. KOSHIJI M, KAGEYAMA Y, PETE EA, HORIKAWA I, BARRETT JC, HUANG LE, HIF-1α induces cell cycle arrest by functionally counteracting Myc, EMBO J, 2004, 23(9):1949-1956.
32. MAHERALI N, SHRIDHARAN R, XIE W, UTIKAL J, EMINLI S, ARNOLD K, STADTFELD M, YACHECHKO R, TCHIEU J, JAENISCH R, PLATH K, HOCHEDLINGER K, Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution, Cell Stem Cell, 2007, 1(1):55-70.
33. ELKAHWAJI JE, ZHONG W, HOPKINS WJ, BUSHMAN W, Chronic bacterial infection and inflammation incite reactive hyperplasia in a mouse model of chronic prostatitis, Prostate, 2006, 67(1):14-21.
34. DAS D, WOJNO K, IMPERIALE MJ, BK virus as a cofactor in the etiology of prostate cancer in its early stages, J Virol, 2008, 82(6):2705-2714.
35. URISMAN A, MOLINARO RJ, FISCHER N, PLUMMER SJ, CASEY G, KLEIN EA, MALATHI K, MAGI-GALLUZZI C, TUBBS RR, GANEM D, SILVERMAN RH, DERISI JL, Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant, PloS Pathog, 2006, 2(3):e25.
36. ZIPORI D, The nature of stem cells: state rather than entity, Nat Rev Genet, 2004, 5(11):873-878.
37. DUELLI DM, PADILLA-NASH HM, BERMAN D, MURPHY KM, RIED T, LAZEBNIK Y, A virus causes cancer by inducing massive chromosomal instability through cell fusion, Curr Biol, 2007, 17(5):431-437.
38. COLOTTA F, ALLAVENA P, SICA A, GARLANDA C, MANTOVANI A, Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability, Carcinogenesis, 2009, 30(7):1073-1081.
39. HOUGHTON J, STOICOV C, NOMURA S, ROGERS AB, CARLSON J, LI H, CAI X, FOX JG, GOLDENRING JR, WANG TC, Gastric cancer originating from bone-marrow derived cells, Science, 2004, 306(5701):1568-1571.
40. DEZORELLA N, PEVSNER-FISCHER M, DEUTSCH V, KAY S, BARON S, STERN R, TAVOR S, NAGLER A, NAPARSTEK E, ZIPORI D, KATZ BZ, Mesenchymal stromal cells revert multiple myeloma cells to less differentiated phenotype by the combined activities of adhesive interactions and interleukin-6, Exp Cell Res, 2009, 315(11):1904-1913.
41. DITTMAR T, NAGLER C, SCHWITALLA S, REITH G, NIGGEMANN B, ZÄNKER KS, Recurrence cancer stem cells - made by cell fusion?, Med Hypotheses, 2009, 73(4):542-547.
42. GRACE VM, SHALINI JV, IEKHA TT, DEVARAJ SN, DEVARAJ H, Co-overexpression of p53 and bcl-2 proteins in HPVinduced squamous cell carcinoma of the uterine cervix, Gynecol Oncol, 2003, 91(1):51-58.
43. PARRIS G, The cell clone ecology hypothesis and the cell fusion model of cancer progression and metastasis (II): three pathways for spontaneous cell-cell fusion and escape from the intercellular matrix, Med Hypotheses, 2006, 67(1):172-176.
44. PAGET S, The distribution of secondary growths in cancer of the breast, Lancet, 1889, 1:571-573.
45. EWING J, Neoplastic diseases, 6th edition, WB Saunders, Philadelphia, 1928.
46. HAIER J, NICOLSON GL, Tumor cell adhesion under hydrodynamic conditions of fluid flow, APMIS, 2001, 109(4):241-262.
47. ENNS A, GASSMANN P, SCHLÜTER K, KORB T, SPIEGEL HU, SENNINGER N, HAIER J, Integrins can directly mediate metastatic tumor cell adhesion within the liver sinusoids, J Gastrointest Surg, 2004, 8(8):1049-1059; discussion 1060.
48. NAKAMORI S, KAMEYAMA M, IMAOKA S, FURUKAWA H, ISHIKAWA O, SASAKI Y, KABUTO T, IWANAGA T, MATSUSHITA Y, IRIMURA T, Increased expression of sialyl Lewisx antigen correlates with poor survival in patients with colorectal carcinoma: clinicopathological and immunohistochemical study, Cancer Res, 1993, 53(15):3632-3637.
49. AMADO M, CARNEIRO F, SEIXAS M, CLAUSEN H, SOBRINHOSIMÕES M, Dimeric sialyl-Le(x) expression in gastric carcinoma correlates with venous invasion and poor outcome, Gastroenterology, 1998, 114(3):462-470.
50. BORSIG L, WONG R, HYNES RO, VARKI NM, VARKI A, Synergistic effects of L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis, Proc Natl Acad Sci U S A, 2002, 99(4):2193-2198.
51. JIANG H, CHESS L, Regulation of immune response by T cells, N Engl J Med, 2006, 354(11):1166-1176.
52. HEIMBURG J, YAN J, MOREY S, GLINSKII OV, HUXLEY VH, WILD L, KLICK R, ROY R, GLINSKY VV, RITTENHOUSEOLSON K, Inhibition of spontaneous breast cancer metastasis by anti-Thomsen-Friedenreich antigen monoclonal antibody JAA-F11, Neoplasia, 2006, 8(11):939-948.
53. MBEUNKUI F, JOHANN DJ JR, Cancer and the tumor microenvironment: a review of an essential relationship, Cancer Chemother Pharmacol, 2009, 63(4):571-582.
54. GASSMANN P, HAIER J, The tumor cell-host organ interface in the early onset of metastatic organ colonisation, Clin Exp Metastasis, 2008, 25(2):171-181.
55. HAYASHI C, RITTLING S, HAYATA T, AMAGASA T, DENHARDT D, EZURA Y, NAKASHIMA K, NODA M, Serum osteopontin, an enhancer of tumor metastasis to bone, promotes B16 melanoma cell migration, J Cell Biochem, 2007, 101(4):979-986.
56. DESAI B, ROGERS MJ, CHELLAIAH MA, Mechanisms of osteopontin and CD44 as metastatic principles in prostate cancer cells, Mol Cancer, 2007, 6:18.
57. HYNES RO, The extracellular matrix: not just pretty fibrils, Science, 2009, 326(5957):1216-1219.
58. VANDERCAPPELLEN J, VAN DAMME J, STRUYF S, The role of CXC chemokines and their receptors in cancer, Cancer Lett, 2008, 267(2):226-244.
59. PHATAK P, COOKSON JC, DAI F, SMITH V, GARTENHAUS RB, STEVENS MF, BURGER AM, Telomere uncapping by the G-quadruplex ligand RHPS4 inhibits clonogenic tumour cell growth in vitro and in vivo consistent with a cancer stem cell targeting mechanism, Br J Cancer, 2007, 96(8):1223-1233.
60. DIKMEN ZG, GELLERT GC, JACKSON S, GRYAZNOV S, TRESSLER R, DOGAN P, WRIGHT WE, SHAY JW, In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor, Cancer Res, 2005, 65(17):7866-7873.
61. DUBROVSKA A, KIM S, SALAMONE RJ, WALKER JR, MAIRA SM, GARCÍA-ECHEVERRÍA C, SCHULTZ PG, REDDY VA, The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations, Proc Natl Acad Sci U S A, 2009, 106(1):268-273.
62. YOU L, HE B, XU Z, UEMATSU K, MAZIERES J, MIKAMI I, REGUART N, MOODY TW, KITAJEWSKI J, MCCORMICK F, JABLONS DM, Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells, Oncogene, 2004, 23(36):6170-6174.
63. TREMBLAY MR, NESLER M, WHEATHERHEAD R, CASTRO AC, Recent patents for Hedgehog pathway inhibitors for the treatment of malignancy, Expert Opin Ther Pat, 2009, 19(8):1039-1056.
64. RUDIN CM, HANN CL, LATERRA J, YAUCH RL, CALLAHAN CA, FU L, HOLCOMB T, STINSON J, GOULD SE, COLEMAN B, LORUSSO PM, VON HOFF DD, DE SAUVAGE FJ, LOW JA, Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449, N Engl J Med, 2009, 361(12):1173-1178.
65. CREA F, MATHEWS LA, FARRAR WL, HURT EM, Targeting prostate cancer stem cells, Anticancer Agents Med Chem, 2009, 9(10):1105-1113.
66. BESANÇON R, VALSESIA-WITTMANN S, PUISIEUX A, DE FROMENTEL CC, MAGUER-SATTA V, Cancer stem cells: the emerging challenge of drug targeting, Curr Med Chem, 2009, 16(4):394-416.
67. PORVASNIK S, SAKAMOTO N, KUSMARTSEV S, ERUSLANOV E, KIM WJ, CAO W, URBANEK C, WONG D, GOODISON S, ROSSER CJ, Effects of CXCR4 antagonist CTCE-9908 on prostate tumor growth, Prostate, 2009, 69(13):1460-1469.